New Technology Repairs and Regenerates Heart Cells After a Heart Attack

Myocarditis Young Man Heart Disease Concept

Innovative conclusions by UH scientists have the prospective to grow to be a powerful scientific system for treating heart ailment.

A “powerful scientific strategy” for managing heart ailment may final result from the latest discovery.

Robert Schwartz

Robert Schwartz, Hugh and Lillie Cranz Cullen Distinguished Professor of biology and biochemistry, led the reports printed in the Journal of Cardiovascular Growing old. Credit rating: College of Houston

College of Houston scientists have created a groundbreaking method that, in mice, not only restores the coronary heart muscle mass cells just after a myocardial infarction (or heart assault) but also can help the cells regenerate.

According to Robert Schwartz, Hugh Roy and Lillie Cranz Cullen Distinguished Professor of biology and biochemistry at the UH Faculty of Natural Sciences and Mathematics, the floor-breaking discovery, which was published in the Journal of Cardiovascular Growing older, has the possible to build into a impressive scientific technique for dealing with coronary heart illness in people today.

The progressive strategy used by the analyze workforce provides mutant transcription aspects, which are proteins that control the conversion of RNA, to mice hearts using synthetic messenger ribonucleic acid (mRNA).

“No one has been able to do this to this extent and we think it could become a possible treatment for humans,” said Schwartz, who led the study with recent Ph.D. graduate Siyu Xiao and Dinakar Iyer, a research assistant professor of biology and biochemistry.

Synthetic mRNA contributes to stem cell-like growth

The researchers demonstrated that two mutated transcription factors, Stemin and YAP5SA, work in tandem to increase the replication of cardiomyocytes, or heart muscle cells, isolated from mouse hearts. These experiments were conducted in vitro on tissue culture dishes.

“What we are trying to do is dedifferentiate the cardiomyocyte into a more stem cell-like state so that they can regenerate and proliferate,” Xiao said.

Stemin turns on stem cell-like properties from cardiomyocytes. Stemin’s crucial role in their experiments was discovered by Iyer, who said the transcription factor was a “game changer.” Meanwhile, YAP5SA works by promoting organ growth that causes the myocytes to replicate even more.

MI mmRNA Heart Treatment

The figure shows an example of a repair of an infarcted adult mouse heart in vivo, made possible through injections of a combination of STEMIN and YAP5SA mRNA. After four weeks, sectioned hearts stained red showed a significant reduction of infarcted area Credit: The Journal of Cardiovascular Aging

In a separate finding published in the same journal, the team will report that Stemin and YAP5SA repaired damaged mouse hearts in vivo. Notably, myocyte nuclei replicated at least 15-fold in 24 hours following heart injections that delivered those transcription factors.

Bradley McConnell, professor of pharmacology, and graduate student Emilio Lucero in the UH College of Pharmacy collaborated on the study by producing the infarcted adult mouse model.

“When both transcription factors were injected into infarcted adult mouse hearts, the results were stunning,” Schwartz said. “The lab found cardiac myocytes multiplied quickly within a day, while hearts over the next month were repaired to near normal cardiac pumping function with little scarring.”

An added benefit of using synthetic mRNA, according to Xiao, is that it disappears in a few days as opposed to viral delivery. Gene therapies delivered to cells by viral vectors raise several biosafety concerns because they cannot be easily stopped. mRNA-based delivery, on the other hand, turns over quickly and disappears.

A Limited Number of Cardiomyocytes

Schwartz and Iyer worked on this study for several years, and Xiao focused on this research throughout her doctoral studies at UH. She graduated in the fall of 2020.

“I feel honored and lucky to have worked on this,” Xiao said. “This is a huge study in heart regeneration especially given the smart strategy of using mRNA to deliver Stemin and YAP5SA.”

The findings are especially important because less than 1{4224f0a76978c4d6828175c7edfc499fc862aa95a2f708cd5006c57745b2aaca} of adult cardiac muscle cells can regenerate. “Most people die with most of the same cardiomyocytes they had in the first month of life,” she said. When there is a heart attack and heart muscle cells die, the contracting ability of the heart can be lost.

Reference: “Mutant SRF and YAP synthetic modified mRNAs drive cardiomyocyte nuclear replication” by Siyu Xiao, Rui Liang, Azeez B. Muili, Xuanye Cao, Stephen Navran, Robert J. Schwartz and Dinakar Iyer, 19 May 2022, The Journal of Cardiovascular Aging.
DOI: 10.20517/jca.2022.17

The study was funded in part through the University of Houston, a Cullen Endowed Chair, the Texas Higher Education Coordinating Board, Leducq Foundation, and a sponsored research agreement from Animatus Biosciences, LLC.

New technology can quickly, non-invasively identify possible arrhythmia source in heart

The awareness that recovering Covid-19 individuals facial area an improved hazard of cardiac arrhythmia issues, is just one element contributing to the want to obtain ways to properly discover probable resources of arrhythmia in recovered sufferers. An arrhythmia is a difficulty with the fee or rhythm of heartbeats — in other word, individuals with this issue suffers from the coronary heart beating too rapidly or too slow or with an irregular pattern. 

Latest arrhythmia mapping techniques involve a catheter to navigate by means of the heart and map prospective resources of arrhythmia, proving not only invasive, but time and labor intensive to boot.

But San Diego, California-based mostly Vektor Health-related is on the lookout to present an substitute. It declared past week that College of California, San Diego Health is the 1st healthcare facility to use its Food and drug administration cleared vMap know-how for mapping the coronary heart for the duration of cardiac ablation strategies. As a result of ablation, warmth or chilly therapy is used by way of a catheter to block irregular electric alerts with the target to restore a regular coronary heart conquer.

Vektor Health care claims that its vMap engineering is non-invasive, speedy, and a lot less labor intensive than present catheter mapping procedures. The technologies is ready to establish likely arrhythmia resources any where in the heart working with only the details from an ECG to do so.  This non-invasive strategy identifies resources of each stable and unstable arrhythmia from all four coronary heart chambers, the septal wall, and outflow tracts. It involves no catheter, nor is the affected person uncovered to additional radiation owing to extended fluoroscopic use.

“vMap is the very first technological know-how made to discover equally focal- and fibrillation-sort arrhythmia resources anywhere in the coronary heart in less than three minutes by utilizing only the details from a regular 12-guide ECG,” explained Mike Monko, Vektor’s co-founder and CEO in an e mail.

vMap Atrial Fibrillation mapping.

Vektor hopes its merchandise will shorten method time and boost initially-move ablation achievements as its method consolidates the mapping approach and provides equally 2D as properly as 3D sizzling location maps of the whole coronary heart.

“The advantage of this process is the medical professional spends fewer time locating the supply and can immediately hone in on the target zone. In fact, we’ve experienced users share that vMap could have saved them several hours as they would have recognized the place to go initial,” Monko declared.

Vektor touts that vMap can map the resources of arrhythmia by itself, without having the require for added devices or imaging, according to a news launch. Nevertheless, it notes vMap can do the job as a complement to traditional invasive electro-anatomical mapping programs if desired, which may well be applicable in both of those preparing and procedural settings, in accordance to a press release.

Vektor has elevated $15 million, in accordance to Monko. In November, it shut a Protected spherical to fund the start of vMap at choose cardiovascular centers in the course of the United States in 2022.

Monko declined to establish buyers, but said the list incorporates “experts in the fields of cardiology, finance, and intellectual home.”

As for Vektor’s valuation? He demurred there as nicely.

“The market place will in the end determine our valuation. So significantly, investors are enthusiastic and extremely supportive of our professional roll out strategies,” Monko extra.

 

Photograph: Picture: hudiemm, Getty Visuals and Vektor Health care

 

Why sensor technology could be at the heart of future health

Dr Aoife Morrin believes the ‘holy grail’ of sensor technology lies in the ability to monitor our health via biomarkers in the skin.

Sensors have become central to many technological advances in recent years and this is reflected in the growing investment in the space.

In 2018, Queen’s University Belfast spin-out Causeway Sensors raised £1.2m for its nanotechnology to enable pathogen detection. In 2020, Cork Institute of Technology, now part of Munster Technological University, was chosen to lead a €3.8m EU project to build tiny sensors for drones to monitor the environment. And earlier this year, French medtech start-up Grapheal, which specialises in graphene-based wearable biosensors, secured €1.9m in funding.

The advancements in sensors are seen across several industries, from farming to pipe maintenance. But one of the major real-world applications is within the area of medical devices and healthcare.

Dr Aoife Morrin is director of the National Centre for Sensor Research (NCSR) and associate professor at the School of Chemical Sciences at Dublin City University (DCU).

The NCSR works on many aspects of sensor platform design, with chemistry, biology, physics and engineering labs all working together.

The centre has research groups working in a variety of areas, including wireless transduction technology for implantable sensors, cell-based detection using novel luminescent probes and the 3D printing of new biomimetic materials.

The holy grail of sensors

Morrin’s own research group has been focused on wearable sensors for health diagnostics.

“The holy grail in this space is to be able to continuously monitor our health via biomarkers that we can access in the skin. Achieving this would enable personalised management of chronic disease, for example – so instead of attending a clinic once a month to take a blood sample, we could perform the same analysis at home daily or even hourly using a wearable that monitors biochemical changes in the skin.”

‘We see exciting opportunities for new wearable gas sensors’
– AOIFE MORRIN

There have been plenty of exciting advancements in skin sensors in recent years. Last year, researchers found a way to print sensors onto skin without heat, potentially creating a more accurate way of taking biometric measurements than wearable devices.

And earlier this year, a team at Trinity College Dublin created a flexible graphene-based sensor that could be a “considerable step forward” in the area of wearable diagnostic devices.

But while these sensors could enable better disease management and more effective therapies, Morrin said delivering on these wearables is easier said than done.

“Even accessing these biomarkers from skin presents a major challenge. Some researchers use microneedles – shallow needles that penetrate the skin – to access the interstitial fluid but avoid contact with the nerve endings,” she said.

“We have taken a different approach. We are interested in the gas, or volatile, emission that comes off skin. Volatiles are being released continuously from the glands and the microbes that are resident on our skin and we want to understand if there are new biomarkers or signatures of disease within this volatile emission.

“If there are, and we believe there are, then we see exciting opportunities for new wearable gas sensors that can continuously monitor this emission and give us insights about our health.”

Recognising challenges

The field of sensor technology research is incredibly exciting and when the potential real-life applications are laid out in front of us, it’s easy to get carried away. However, Morrin said this excitement can sometimes lead to a tendency to oversell or overpromise when it comes to publishing research.

She said that while wearables technology is improving all the time, there are still massive challenges to overcome in designing suitable biochemical sensor interfaces.

“How can we access and sample clinically relevant skin biomarkers robustly and in a representative manner? How can we design sensor surfaces to be highly selective for target detection? What can we do to ensure sufficient analytical sensitivity of our sensors? And how do we retain the integrity of these sensors for continuous monitoring for extended periods of time?

“These are all challenges that the research community needs to fully address before wearable biochemical sensors can become a technology that will have an impact on our lives.”

Morrin was appointed director of the NCSR in March of this year. She sees her role as both simplistic but also challenging.

“I have a role in incentivising collaborations and cross-fertilisation of research ideas across the different schools and even faculties to translate our discipline-specific expertise in DCU into new sensing technologies,” she said.

“This sounds simple but actually involves a lot of effort not only on my part, devising mechanisms to enable this, but it also requires effort from all our academics to push this agenda and to drive a culture of genuine collaboration in the centre. We are getting there, and for instance we hope to launch a new collaborative grant scheme for our NCSR members in the new year – watch this space!”

Don’t miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic’s digest of need-to-know sci-tech news.